Skip to content

Evaluation of safety and efficacy of skin care formulation

PRIMARY OBJECTIVE To evaluate the in-vivo efficacy and safety of a skin care formulation in terms of in terms of skin brightening on healthy female subjects. SECONDARY OBJECTIVE To evaluate the in-vivo efficacy of a skin care formulation in terms of improvement in skin hydration and improvement in skin smoothness on healthy female subjects.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044838
Enrollment
56
Registered
2022-08-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Sunscreen Serum: Approximately 0.5-1gm of the product to be applied on whole face The test product to be applied thrice in a day in the morning, afternoon & evening (every 4hours while

Sponsors

DPKA Universal Consumer Ventures Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Indian Female subjects. 2 Healthy subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup) 3 Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar, acne�.) Specific criteria 4 Having wheatish to dark complexion. 5 Having dry skin. 6 Subjects who are passing in skin sensitivity test (only for 13 females)

Exclusion criteria

Exclusion criteria: 1 Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2 Having refused to give her assent by not signing the consent form 3 Taking part in another study liable to interfere with this study 4 Being insulin-dependent diabetic or non insulin-dependent diabetic with a recent therapy (less than 6 months) 5 Having a progressive asthma (either under treatment or last fit in the last 2 years) 6 Being epileptic. 7 Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 8 Having cutaneous hypersensitivity 9 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products. 10 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 11 Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months. 12 Having changed her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit 13 Having applied a cosmetic product (included make-up) or skin care product on the studied areas the day of the study (only face cleaned with water is accepted) 14 Refusing to follow the restrictions below during the study: -Do not take part in any family planning activities leading to pregnancy and breastfeeding -Do not take part in another study liable to interfere with this study. -Do not take medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol). -Do not change her cosmetic habits apart from the particular conditions mentioned in the protocol, on the studied anatomic unit. -During the study: Do not use other cosmetic products or skin care products other than the tested products to the studied areas. (only standard facewash is accepted). The day of the measurements: No test product must be used (only face cleaned with water is accepted) Specific criteria 15 Having started, changed or interrupted one hormonal treatment (hormonal contraception, Hormone Replacement Therapy) during the past 3 months. 16 Having started, changed or stopped his/her tobacco consumption (for smokers consuming more than 10 cigarettes per day) in the previous 6 months 17 Having taken a medicinal treatment which could lead to hyper pigmentation (phenyto�¯n, amiodarone, metals, minocyclineâ�¦) in the previous 6 months 18 Taking oral supplements with major or minor effect on whitening of skin (e.g. vitamin C, beta caroteneâ�¦) 19 Having had beauty treatment (e.g. skin cleansing, exfoliation, scrub, mask â�¦) or having applied self-tanning products in the week preceding the start of the study 20 Having applied products with anti-wrinkle action (Retinoic acid, retinol, retinaldehyde, isotretinoin, A.H.A...) in the 2 weeks preceding the start of the study 21 Having applied products with a depigmenting action (hydroquinone or derivatesâ�¦) in the 4 weeks preceding the start of the study. 22 Having undergone physical and/or chemical treatments of the spots (liquid ni

Design outcomes

Primary

MeasureTime frame
skin brightening, skin safetyTimepoint: Baseline, 30 min after product application, 7 days, 14 days and 28 days

Secondary

MeasureTime frame
improvement in skin hydration and improvement in skin smoothnessTimepoint: Baseline, 30 min after product application, 7 days, 14 days and 28 days

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

raji@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026